-
公开(公告)号：US11504433B2
公开(公告)日：2022-11-22
申请号：US17129376
申请日：2020-12-21
发明人： Thomas Carl Hunter , Randall J. Mrsny , Weijun Feng , Tahir Mahmood , Charles Olson , Sally Postlethwaite
IPC分类号： A61K47/64 , C07K14/195 , A61K39/10 , A61K39/02
摘要： The present disclosure provides delivery constructs comprising a carrier coupled to a heterologous payload, wherein coupling of the carrier to the payload can result in transportation of the payload (e.g., a therapeutic payload) into and/or across intact polarized epithelial cells (e.g., epithelial cells of the gut of a mammal). The delivery construct can be part of a pharmaceutical composition that can be orally administered to a subject to provide for improved, effective therapies for treatment of, e.g., inflammatory diseases or autoimmune diseases.
-
公开(公告)号：US20210100911A1
公开(公告)日：2021-04-08
申请号：US16884456
申请日：2020-05-27
IPC分类号： A61K47/64 , C07K14/195
摘要： The present disclosure provides delivery constructs comprising a carrier coupled to a heterologous payload, wherein coupling of the carrier to the payload can result in transportation of the payload (e.g., a therapeutic payload) into and/or across intact polarized epithelial cells (e.g., epithelial cells of the gut of a mammal). The delivery construct can be part of a pharmaceutical composition that can be orally administered to a subject to provide for improved, effective therapies for treatment of, e.g., inflammatory diseases or autoimmune diseases.
-
公开(公告)号：US20220089666A1
公开(公告)日：2022-03-24
申请号：US17529138
申请日：2021-11-17
发明人： Randall J. Mrsny , Tahir Mahmood , Amir Porat , Charles Olson , Sally Postlethwaite , Weijun Feng , Khushdeep Mangat
IPC分类号： C07K14/54 , C07K1/14 , C07K1/18 , C07K1/34 , C07K1/36 , C07K14/28 , A61K47/32 , A61K47/34 , A61K47/38
摘要： Described herein are cholix-IL-10 fusion proteins, and methods of use thereof, which can be characterized by a distinct response in an individual when administered. This distinct response can comprise changes in levels of one or more markers in the individual and/or co-localization of IL-10 in the Lamina propria of the individual. Further described herein, in some embodiments, are oral formulations of the cholix-IL-10 fusion proteins. Described herein are methods for the purification of an IL-10 delivery construct, including methods for refolding and enrichment, which can result in maintenance of a high percentage of the IL-10 delivery constructs in the biologically active dimer form. Described herein are oral formulations configured for site-specific release of a therapeutic protein in the small intestines or colon. In some cases, the therapeutic protein is in the form of a dimer, such as an IL-10 delivery construct capable of crossing the gut epithelium.
-
公开(公告)号：US20240009316A1
公开(公告)日：2024-01-11
申请号：US18052455
申请日：2022-11-03
发明人： Randall J. Mrsny , Charles Olson , Sally Postlethwaite , Thomas Carl Hunter , Tahir Mahmood , Weijun Feng
IPC分类号： A61K47/64 , C07K14/195 , A61K39/02
CPC分类号： A61K47/6415 , C07K14/195 , A61K39/107
摘要： The present disclosure provides delivery constructs comprising a carrier coupled to a heterologous payload, wherein coupling of the carrier to the payload can result in transportation of the payload (e.g., a therapeutic payload) into and/or across intact polarized epithelial cells (e.g., epithelial cells of the gut of a mammal). The delivery construct can be part of a pharmaceutical composition that can be orally administered to a subject to provide for improved, effective therapies for treatment of, e.g., inflammatory diseases or autoimmune diseases.
-
公开(公告)号：US11466067B2
公开(公告)日：2022-10-11
申请号：US17529138
申请日：2021-11-17
发明人： Randall J. Mrsny , Tahir Mahmood , Amir Porat , Charles Olson , Sally Postlethwaite , Weijun Feng , Khushdeep Mangat
IPC分类号： C07K14/54 , C07K1/14 , C07K1/18 , C07K1/34 , C07K1/36 , C07K14/28 , A61K47/32 , A61K47/34 , A61K47/38 , A61K38/00
摘要： Described herein are cholix-IL-10 fusion proteins, and methods of use thereof, which can be characterized by a distinct response in an individual when administered. This distinct response can comprise changes in levels of one or more markers in the individual and/or co-localization of IL-10 in the Lamina propria of the individual. Further described herein, in some embodiments, are oral formulations of the cholix-IL-10 fusion proteins. Described herein are methods for the purification of an IL-10 delivery construct, including methods for refolding and enrichment, which can result in maintenance of a high percentage of the IL-10 delivery constructs in the biologically active dimer form. Described herein are oral formulations configured for site-specific release of a therapeutic protein in the small intestines or colon. In some cases, the therapeutic protein is in the form of a dimer, such as an IL-10 delivery construct capable of crossing the gut epithelium.
-
公开(公告)号：US11214606B2
公开(公告)日：2022-01-04
申请号：US17169396
申请日：2021-02-05
发明人： Randall J. Mrsny , Tahir Mahmood , Amir Porat , Charles Olson , Sally Postlethwaite , Weijun Feng , Khushdeep Mangat
摘要： Described herein are cholix-IL-10 fusion proteins, and methods of use thereof, which can be characterized by a distinct response in an individual when administered. This distinct response can comprise changes in levels of one or more markers in the individual and/or co-localization of IL-10 in the Lamina propria of the individual. Further described herein, in some embodiments, are oral formulations of the cholix-IL-10 fusion proteins. Described herein are methods for the purification of an IL-10 delivery construct, including methods for refolding and enrichment, which can result in maintenance of a high percentage of the IL-10 delivery constructs in the biologically active dimer form. Described herein are oral formulations configured for site-specific release of a therapeutic protein in the small intestines or colon. In some cases, the therapeutic protein is in the form of a dimer, such as an IL-10 delivery construct capable of crossing the gut epithelium.
-
公开(公告)号：US20210338828A1
公开(公告)日：2021-11-04
申请号：US17235567
申请日：2021-04-20
发明人： Randall J. Mrsny , Tahir Mahmood , Charles Olson , Weijun Feng
摘要： The present disclosure provides non-naturally occurring fusion molecules comprising therapeutic cargo moieties, such as IL-22 with a carrier. The disclosure also provides methods and compositions for the production, purification, refolding, formulation, and administration of fusion molecules. Methods and for using the purified molecules to treat and prevent diseases or disorders are also provided herein.
-
公开(公告)号：US11324833B2
公开(公告)日：2022-05-10
申请号：US16884456
申请日：2020-05-27
发明人： Randall J. Mrsny , Charles Olson , Sally Postlethwaite , Thomas Carl Hunter , Tahir Mahmood , Weijun Feng
IPC分类号： A61K39/02 , A61K47/64 , C07K14/28 , C07K14/195
摘要： The present disclosure provides delivery constructs comprising a carrier coupled to a heterologous payload, wherein coupling of the carrier to the payload can result in transportation of the payload (e.g., a therapeutic payload) into and/or across intact polarized epithelial cells (e.g., epithelial cells of the gut of a mammal). The delivery construct can be part of a pharmaceutical composition that can be orally administered to a subject to provide for improved, effective therapies for treatment of, e.g., inflammatory diseases or autoimmune diseases.
-
公开(公告)号：US20210171597A1
公开(公告)日：2021-06-10
申请号：US17169396
申请日：2021-02-05
发明人： Randall J. Mrsny , Tahir Mahmood , Amir Porat , Charles Olson , Sally Postlethwaite , Weijun Feng , Khushdeep Mangat
摘要： Described herein are cholix-IL-10 fusion proteins, and methods of use thereof, which can be characterized by a distinct response in an individual when administered. This distinct response can comprise changes in levels of one or more markers in the individual and/or co-localization of IL-10 in the Lamina propria of the individual. Further described herein, in some embodiments, are oral formulations of the cholix-IL-10 fusion proteins. Described herein are methods for the purification of an IL-10 delivery construct, including methods for refolding and enrichment, which can result in maintenance of a high percentage of the IL-10 delivery constructs in the biologically active dimer form. Described herein are oral formulations configured for site-specific release of a therapeutic protein in the small intestines or colon. In some cases, the therapeutic protein is in the form of a dimer, such as an IL-10 delivery construct capable of crossing the gut epithelium.
-
公开(公告)号：US11027020B2
公开(公告)日：2021-06-08
申请号：US16902256
申请日：2020-06-15
摘要： The present disclosure provides non-naturally occurring fusion molecules comprising therapeutic cargo moieties, such as IL-22 with a carrier. The disclosure also provides methods and compositions for the production, purification, refolding, formulation, and administration of fusion molecules. Methods and for using the purified molecules to treat and prevent diseases or disorders are also provided herein.
-
-
-
-
-
-
-
-
-
搜索结果
11 条记录 (耗时 0.018 秒)
